Edgewise Therapeutics (EWTX) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Vericel (VCEL) over the past year, gaining 155.6% versus a gain of 17.3%. Over five years, EWTX leads with a +121.1% price change compared with -21.1% for VCEL. Edgewise Therapeutics is the larger company by market cap ($4.24 billion vs $2.05 billion), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | VCEL |
|---|---|---|
| Share price | $39.06 | $40.10 |
| Market cap | $4.24B | $2.05B |
| 1-day change | -0.43% | +0.12% |
| YTD return | +58.09% | +11.22% |
| 1-year return | +155.57% | +17.35% |
| 5-year return | +121.14% | -21.15% |
| P/E ratio (TTM) | — | 85.32 |
| Forward P/E | — | 47.40 |
| EPS (TTM) | $-1.86 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $276.26M |
| Revenue growth (YoY) | — | +16.45% |
| Net income (latest FY) | $-167.79M | $16.52M |
| Gross margin | — | 74.42% |
| Operating margin | — | 4.00% |
| Net margin | — | 5.98% |
| 52-week high | $48.51 | $49.32 |
| 52-week low | $14.25 | $28.95 |
| Distance from 52-week high | -19.48% | -18.69% |
| Analyst consensus | buy | none |
| Avg. price target upside | +34.72% | +51.05% |
| Average volume | 1.34M | 507.54K |
| Shares outstanding | 108.60M | 51.21M |
| Employees | 127 | 398 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Edgewise Therapeutics is about 2.1 times larger than Vericel by market value ($4.24B vs $2.05B).
- EWTX has outperformed VCEL by 138.2 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
EWTX vs VCEL FAQ
Which is bigger, Edgewise Therapeutics or Vericel?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.24B compared with $2.05B for Vericel (VCEL).
Which stock has performed better over the past year, EWTX or VCEL?
EWTX returned +155.57% over the past 12 months, compared with +17.35% for VCEL (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Vericel in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Edgewise Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Vericel.